Burnham to Study Drug Targets for J&J | GenomeWeb

NEW YORK (GenomeWeb News) — The Burnham Institute for Medical Research has inked an assay-development and license agreement with Johnson & Johnson Pharmaceutical Research and Development that will give the drug maker access to some of Burnham's high-throughput screening technologies to study drug targets for inflammatory diseases, Burnham said on Monday.

Burnham CEO John Reed said in a statement that he thinks the collaboration, which is the institute's first with a large pharma, "will foster the discovery of drug products with real clinical potential."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.